|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 9/20 | |
| A61K 9/28 | |||
| A61K 38/10 | |||
| A61P 1/00 | |||
| A61P 29/02 | |||
| A61P 13/10 |
| (11) | Number of the document | 3302440 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16729739.9 |
| Date of filing the European patent application | 2016-06-03 | |
| (97) | Date of publication of the European application | 2018-04-11 |
| (45) | Date of publication and mention of the grant of the patent | 2021-01-06 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2016/035886 |
| Date | 2016-06-03 |
| (87) | Number | WO 2016/197042 |
| Date | 2016-12-08 |
| (30) | Number | Date | Country code |
| 201562171462 P | 2015-06-05 | US | |
| 201662339462 P | 2016-05-20 | US |
| (72) |
HASHASH, Ahmad, US
|
| (73) |
Ironwood Pharmaceuticals, Inc.,
100 Summer Street, Suite 2300, Boston, MA 02110,
US
|
| (54) | MODIFIED OR TARGETED RELEASE FORMULATIONS OF LINACLOTIDE |
| MODIFIED OR TARGETED RELEASE FORMULATIONS OF LINACLOTIDE |